Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers

Drug and Alcohol Dependence

Volumn 106, Issue 2-3, 2010, Pages 173-180

  De La Garza II, Richard ^b   Zorick, Todd ^a   London, Edythe D ^a   Newton, Thomas F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; Dependence; Methamphetamine; Modafinil

Indexed keywords

METHAMPHETAMINE; MODAFINIL; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; VOLUNTEER;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; MALE; METHAMPHETAMINE; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); PATIENT DISCHARGE; PLACEBOS; REINFORCEMENT (PSYCHOLOGY); UNITED STATES;

EID: 73549091936     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.08.013     Document Type: Article

References (38)

1. Camacho A., and Stein M.B. Modafinil for social phobia and amphetamine dependence. Am. J. Psychiatry 159 (2002) 1947-1948
2. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., and Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
3. Chu P.W., Seferian K.S., Birdsall E., Truong J.G., Riordan J.A., Metcalf C.S., Hanson G.R., and Fleckenstein A.E. Differential regional effects of methamphetamine on dopamine transport. Eur. J. Pharmacol. 590 (2008) 105-110
4. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., Rowan A., Poole S., White L., and O'Brien C.P. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 70 (2003) 29-37
5. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., and O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30 (2005) 205-211
6. De La Garza R., Mahoney J.J., Culbertson C., Shoptaw S., and Newton T.F. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol. Biochem. Behav. 89 (2008) 200-208
7. De La Garza R., Shoptaw S., and Newton T.F. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int. J. Neuropsychopharmacol. 11 (2008) 729-741
8. Deroche-Gamonet V., Darnaudéry M., Bruins-Slot L., Piat F., Le Moal M., and Piazza P.V. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161 (2002) 387-395
9. Elkashef A.M., Rawson R.A., Anderson A.L., Li S.H., Holmes T., Smith E.V., Chiang N., Kahn R., Vocci F., Ling W., Pearce V.J., McCann M., Campbell J., Gorodetzky C., Haning W., Carlton B., Mawhinney J., and Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33 (2008) 1162-1170
10. Fleckenstein A.E., Volz T.J., and Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56 (2009) 133-138
11. Gold L.H., and Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 126 (1996) 286-292
12. Hart C.L., Haney M., Vosburg S.K., Rubin E., and Foltin R.W. Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav. Pharmacol. 18 (2007) 71-75
13. Hart C.L., Haney M., Vosburg S.K., Rubin E., and Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33 (2008) 761-768
14. Jasinski D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacology 14 (2000) 53-60
15. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., and Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319 (2006) 561-569
16. Martin W.R., Sloan J.W., Sapira J.D., and Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12 (1971) 245-258
17. McElhiney M.C., Rabkin J.G., Rabkin R., and Nunes E.V. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am. J. Drug Alcohol Abuse 35 (2009) 34-37
18. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., and White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 100 (2005) 1320-1329
19. Mignot E., Nishino S., Guilleminault C., and Dement W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17 (1994) 436-437
20. Newton T.F., Kalechstein A.D., Hardy D.J., Cook I.A., Nestor L., Ling W., and Leuchter A.F. Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin. Neurophysiol. 115 (2004) 194-198
21. Newton T.F., Roache J.D., De La Garza R., Fong T., Wallace C.L., Li S.H., Elkashef A., Chiang N., and Kahn R. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 182 (2005) 426-435
22. Newton T.F., De La Garza R., Kalechstein A.D., and Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol. Biochem. Behav. 82 (2005) 90-97
23. Newton T.F., Roache J.D., De La Garza R., Fong T., Wallace C.L., Li S.H., Elkashef A., Chiang N., and Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31 (2006) 1537-1544
24. Newton T.F., Reid M.S., De La Garza R., Mahoney J.J., Abad A., Condos R., Palamar J., Halkitis P.N., Mojisak J., Anderson A., Li S.H., and Elkashef A. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int. J. Neuropsychopharmacol. 11 (2008) 1037-1045
25. Rush C.R., Kelly T.H., Hays L.R., and Wooten A.F. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend. 67 (2002) 311-322
26. Shearer J., Darke S., Rodgers C., Slade T., van Beek I., Lewis J., Brady D., McKetin R., Mattick R.P., and Wodak A. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 104 (2009) 224-233
27. Stoops W.W., Lile J.A., Fillmore M.T., Glaser P.E., and Rush C.R. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology 182 (2005) 186-193
28. Taneja I., Diedrich A., Black B.K., Byrne D.W., Paranjape S.Y., and Robertson D. Modafinil elicits sympathomedullary activation. Hypertension 45 (2005) 612-618
29. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., and Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165 (2003) 260-269
30. Turner D.C., Clark L., Dowson J., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry 55 (2004) 1031-1040
31. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29 (2004) 1363-1373
32. Vansickel A.R., Fillmorex M.T., Hays L.R., and Rush C.R. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers. Am. J. Drug Alcohol Abuse 34 (2008) 293-305
33. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., and Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21 (2001) 9414-9418
34. Volz T.J., Fleckenstein A.E., and Hanson G.R. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction 102 (2007) 44-48
35. Volz T.J., Hanson G.R., and Fleckenstein A.E. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J. Neurochem. 101 (2007) 883-888
36. Walsh S.L., Haberny K.A., and Bigelow G.E. Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150 (2000) 361-373
37. Wong Y.N., King S.P., Laughton W.B., McCormick G.C., and Grebow P.E. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J. Clin. Pharmacol. 38 (1998) 276-282
38. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., Prisinzano T.E., and Baumann M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 329 (2009) 738-746